BSE · 532523 · Pharmaceuticals
Biocon Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹605 Cr with net profit ₹51 Cr — a 8.43% net margin, versus 2.23% the period before.
Shareholding
As of 2026-06-30
- Promoter44.68%
- Public23.8%
- FII8.14%
- DII23.38%
3,92,833 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.35× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #9 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,75,260 Cr | 38.24 | 5.69 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,917 Cr | 216.07 | 3.48 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,12,668 Cr | 20.74 | 4.16 | 18.59% | 18.86% |
| Lupin Limited | ₹1,12,333 Cr | 70.54 | 5 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,796 Cr | 194.2 | 6.61 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,186 Cr | 344.37 | 18.13 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,277 Cr | 430.75 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,812 Cr | 100.76 | 2.45 | 9.25% | 10.5% |
| Biocon Ltd.(this company) | ₹70,007 Cr | 546.71 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,979 Cr | 287.58 | 4.92 | 16.66% | 15.65% |
AI analysis
AI-generated · google/gemini-2.5-flashBiocon Ltd. (symbol: 532523) operates in the Pharmaceuticals sector with a market capitalization of Rs 71372 Cr. The company reported a 3.43% revenue growth, a profit margin of 229.8%, and earnings per share (EPS) of Rs 2.39. Its return on equity (ROE) is 114.44% and return on capital employed (ROCE) is 3.64%. The debt-to-equity ratio stands at 0.61, and it offers a dividend yield of 11%.
Positives
- +The company's return on equity (ROE) is 114.44%.
- +The profit margin is 229.8%.
- +The dividend yield is 11%.
Negatives
- −The return on capital employed (ROCE) is 3.64%, which is lower than the return on equity.
- −The latest reported quarterly net profit for Q4 March 2026 was Rs 125.9 Cr, which is lower than the Rs 143.8 Cr reported in Q3 December 2025.
- −The company has a high PE ratio of 183.24.
Financial Performance
For the year ending March 2026, Biocon Ltd. reported a revenue of Rs 17269.5 Cr and a net profit of Rs 385.6 Cr. Quarter-on-quarter, the revenue for the period ending March 2026 was Rs 4516.6 Cr, increasing from Rs 4173 Cr in December 2025. Net profit for the same quarter was Rs 125.9 Cr, up from Rs 143.8 Cr in December 2025.
Profitability & Returns
Biocon Ltd. achieved a profit margin of 229.8% and an EPS of Rs 2.39. The company's return on equity (ROE) is 114.44%, while the return on capital employed (ROCE) is 3.64%. The price-to-earnings (PE) ratio is 183.24.
Balance Sheet
The company's book value per share is Rs 211.51. Biocon Ltd. has a debt-to-equity ratio of 0.61. There are no reported promoter share pledges.
Ownership & Pledges
As of June 30, 2026, promoter holding in Biocon Ltd. was 44.6759%, public holding was 23.7987%, and institutional holding was 31.5254%. Within institutions, DIIs held 23.3838% and FIIs held 8.1416%. There is no reported promoter pledge.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.